USPTO serial 79309216
MEDIGENE IMMUNOTHERAPIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 27, 2022
- Examiner
- CIANCI, RYAN MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEDIGENE IMMUNOTHERAPIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa C. Pavento
Lisa C. Pavento Meunier Carlin & Curfman LLC999 Peachtree Street NESuite 1300Atlanta, GA 30309Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for humans and animals, vaccines, serums for medical purposes, and diagnostic preparations for medical purposes for treating cancer, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptors, and genetically modified cells for determining the type and existence of a tumour in a patient, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins and cells, namely, immune cells carrying a target specific effector protein, protein conjugates, peptides, enzymes and enzyme preparations, in particular antibodies and t-cell proteins, all for medical purposes; t-cells, dendritic cells other immune system cells, and viruses, all for medical purposes;plant extracts for medical purposes; medicines, vaccines, adjuvants, serums all for immunotherapy and the treatment of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods | ACTIVE | — |
| 042 | Custom molecular biology and biotechnology laboratory services, in particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods to the specifications of others, and in the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others | ACTIVE | — |
| 044 | Medical analysis and medical consulting in connection with the treatment of individuals, in particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and immunotherapy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Medigene Immunotherapies GmbH
- Other trademarks owned by Medigene Immunotherapies GmbH
- Other trademarks owned by Medigene Immunotherapies GmbH
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MEDIGENE IMMUNOTHERAPIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 1, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 6, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 6, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 27, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 27, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 27, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 17, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 11, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 11, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 10, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 28, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 28, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 21, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 21, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 21, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 7, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 7, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 7, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 7, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 7, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 14, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 14, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 14, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 30, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 30, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 30, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 1, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 1, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 27, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 26, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 22, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |